American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw - 2009 update

Australian Endodontic Journal

Volumn 35, Issue 3, 2009, Pages 119-130

  Ruggiero, Salvatore L ^a,b   Dodson, Thomas B ^c,d   Assael, Leon A ^e   Landesberg, Regina ^f   Marx, Robert E ^g   Mehrotra, Bhoomi ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b New York Center for Orthognathic and Maxillofacial Surgery   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; CLINICAL PROTOCOL; DECISION MAKING; DIFFERENTIAL DIAGNOSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAW DISEASE; NEOPLASM; ORAL DRUG ADMINISTRATION; ORAL SURGERY; PRACTICE GUIDELINE; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; TIME;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; CLINICAL PROTOCOLS; DECISION MAKING; DIAGNOSIS, DIFFERENTIAL; DIPHOSPHONATES; HUMANS; INJECTIONS, INTRAVENOUS; JAW DISEASES; NEOPLASMS; ORAL SURGICAL PROCEDURES; OSTEONECROSIS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 77649228795     PISSN: 13291947     EISSN: 17474477     Source Type: Journal    
DOI: 10.1111/j.1747-4477.2009.00213.x     Document Type: Article

References (73)

1. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg 2007; 65: 369.
2. Nussbaum SR, Younger J, Vandepol CJ et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95: 297.
3. Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled, clinical trials. J Clin Oncol 2001; 19: 558.
4. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer study Group. N Engl J Med 1996; 335: 1785.
5. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer study Group. J Clin Oncol 1998; 16: 2038.
6. Hillner BE, Ingle JN, Chelbowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042.
7. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458.
8. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879.
9. Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind placebo-controlled trial. Cancer 2004; 100: 2613.
10. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996; 334: 488.
11. Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16: 593.
12. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III double-blind, comparative trial. Cancer J 2002; 7: 377.
13. Berenson JR, Hillner BE, Kyle RA et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20: 3719.
14. United States Food and Drug Administration. Center for Drug Evaluation and Research. [Cited 11 Nov 2008.] Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. DrugDetails
15. Physicians' desk reference. 57th ed. Montvale, NJ: Medical Economics; 2003.
16. Delmas PD, Meunier PJ. The management of Paget's disease of bone. N Engl J Med 1997; 336: 558.
17. Letocha AD, Cintas HL, Troendle JF et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005; 20: 977.
18. Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 2003; 19: 395.
19. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005; 17: 462.
20. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000; 119: 639.
21. Zein CO, Jorgensen RA, Clarke B et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005; 42: 762.
22. Bone HG, Hosking D, Devogelaer JP et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189.
23. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic [Letter]. J Oral Maxillofac Surg 2003; 61: 1115.
24. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff S. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527.
25. Estilo CL, Van Posnak CH, Williams T et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study. J Clin Oncol Proc Am Soc Clin Oncol 2004; 22: 8088.
26. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis\osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005; 63: 1567.
27. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104: 83.
28. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005; 182: 417.
29. Bagan JV, Jimenez Y, Murillo J et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases (Letter). Oral Oncol 2006; 42: 327.
30. Pires FR, Miranda A, Cardoso ES et al. Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. Oral Dis 2005; 11: 365.
31. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753.
32. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaws and bisphosphonates (Letter). N Engl J Med 2005; 353: 100.
33. Hohnecker JA. Novartis 'Dear Doctor' Precautions added to label of Aredia and Zometa. September 24, 2004.
34. United States Food and Drug Administration Oncologic Drugs Advisory Committee. Combidex Briefing Information. [Cited 14 Aug 2006.] Available from URL: http://www.fda.gov/ohms/dockets/ac/05/briefing/2005-4095b1.htm
35. US food and Drug Administration. Office of Drug Safety Postmarketing Safety Review. [Cited 14 Aug 2006.] Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2_03_04-FDA-TAB3.pdf
36. Dodson TB. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67.
37. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates (Letter). N Engl J Med 2005; 353: 99.
38. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580.
39. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91: 968.
40. Dimopoulos M, Kastritis E, Moulopoulos LA, Melakopoulos I et al. The incidence of osteonecrosis of the jaw in patients with multiple myeloma who receive bisphosphonates depends on the type of bisphosphonate. Blood 2005; 106: 637 (American Society of Hematology Annual Meeting Abstracts).
41. Tosi P, Zamagni E, Cangini D et al. Bisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid. Blood 2005; 106: 3461 (American Society of Hematology Annual Meeting Abstracts).
42. Pozzi S, Marcheselli R, Sacchi S et al. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw. Blood 2005; 106: 5057 (American Society of Hematology Annual Meeting Abstracts).
43. Cafro AM, Barbarano LA, Andriani A et al. Osteonecrosis of the jaw associated with chroninc bisphosphonates therapy: an Italian experience. Blood 2005; 106: 5152 (American Society of Hematology Annual Meeting Abstracts).
44. Zavras AI, Zhu S. Bisphosphonate are associated with increased risk for jaw surgery in medical claims data; is it osteonecrosis? J Oral Maxillofac Surg 2006; 64: 917.
45. Hoff AO, Toth BB, Altundag K et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006 ASCO Annual Meeting Proceedings (post meeting edition). 2006; 24: 8528. [Cited 14 Aug 2006.] Available from URL: http://meeting.jco.org/cgi/content/abstract/24/18_suppl/8528
46. Black DM, Delmas PD, Eastell R et al. HORIZON Pivotal Fracture Trial: once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809.
47. ™ May 2006.
48. American Dental Association. Report of the Council of Scientific Affairs. Expert Panel Recommendations: Dental Management of Patients on Oral Bisphosphonate Therapy. June 2006. [Cited 29 Jun 2006.] Available from URL: http://www.ada.org/prof/resources/topics/osteonecrosis.asp
49. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415.
50. Ault A. Jaw necrosis affects 1 in 1700 on oral bisphosphonates. Intern Med News 41:23, August 1, 2008.
51. Felsenberg D, Hoffmeister B. Necrosis of the jaw after high-dose bisphosphonate therapy. Deatsches Arzteblatt 2006; 103: 3078.
52. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24: 945.
53. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008; 66: 625.
54. Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007; 18: 2015.
55. Hoff AO, Toth BB, Altundag K et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826.
56. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 433.
57. Zervas K, Verrou E, Teleioudis Z et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006; 134: 620.
58. Corso A, Varettoni M, Zappasodi P et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007; 21: 1545.
59. Khamaisi M, Regev E, Yarom N et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007; 92: 1172.
60. Sarasquete ME, Garcia-Sanz R, Marin L et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008; 112: 2709.
61. Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. August 9, 2008 [Epub ahead of print].
62. Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. July 22, 2008 [Epub ahead of print].
63. Mehrotra B, Fantasia J, Ruggiero SL. Outcomes of bisphosphonate related osteonecrosis of the jaw. Importance of staging and management. A large single institution update. J Clin Oncol 2008; 26 (Suppl): 205 ASCO Meeting Abstracts.
64. Rosen HN, Moses AC, Garber J et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of a low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000; 66: 100.
65. Ruggiero SL, Gralow J, Marx RE et al. Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Clin Oncol Pract 2006; 2: 7.
66. Migliorati CA, Casiglia J, Epstein J, Siegel MA, Woo SB. Managing the care of patients with bisphosphonateassociated osteonecrosis. J Am Dent Assoc 2005; 136: 1658.
67. American Association of Endodontists Position Statement. Endodontic Implications of Bisphosphonate-Associated Osteonecrosis of the Jaws. [Cited 14 Aug 2006.] Available from URL: http://www.aae.org/dentalpro/guidelines.htm
68. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonates induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397.
69. Carlson EC. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67.
70. Kademani D, Koka S, Lacy MQ, Rajkumar V. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 2006; 81: 1100.
71. Freiberger JJ. The utility of hyperbaric oxygen in the treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67.
72. Lee CY, David T, Nishime M. Use of platelet-rich plasma in the management of oral bisphosphonate-associated osteonecrosis of the jaw: a report of two cases. J Oral Implantol 2007; 33: 371.
73. National Institutes of Health. Funding Opportunities and Notices Search Results. [Cited 19 Nov 2008.] Available from URL: http://grants.nih.gov/grants/guide/search_results.htm?text_curr=osteonecrosis&scope=pa-rfa&year=active&sort=&Search.x=10&Search.y=8